---
title: "Allarity Therapeutics says stenoparib Phase 3 API manufacturing on track for Q3 2026 completion"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285375039.md"
description: "Allarity Therapeutics announced that the manufacturing of the active pharmaceutical ingredient (API) for stenoparib is on schedule for completion by Q3 2026. The Phase 3 manufacturing campaign is progressing as planned, with all payments completed and no further cash outlays expected. The manufacturing is being conducted at a European CDMO that meets FDA and EMA GMP standards, ensuring a high-quality API is available ahead of critical Phase 2 data and potential pivotal trials."
datetime: "2026-05-06T12:13:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285375039.md)
  - [en](https://longbridge.com/en/news/285375039.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285375039.md)
---

# Allarity Therapeutics says stenoparib Phase 3 API manufacturing on track for Q3 2026 completion

**Allarity Therapeutics reported that the active pharmaceutical ingredient manufacturing campaign for stenoparib is on track for completion no later than Q3 2026.**

**Key Highlights:**

-   API Phase 3 manufacturing campaign progressing per plan, expected completed by Q3 2026 to support pivotal development.
-   Manufacturing at a European CDMO compliant with FDA and EMA GMP standards for late-stage clinical supply.
-   All manufacturing-related payments completed; no additional cash outlays for manufacturing anticipated.
-   Completion timed to ensure higher-standard API is available ahead of anticipated critical Phase 2 data and potential pivotal trial.

Original SEC Filing: Allarity Therapeutics, Inc. \[ ALLR \] - 8-K - May. 06, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ALLR.US](https://longbridge.com/en/quote/ALLR.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)

## Related News & Research

- [LIVE MARKETS-BofA clients flock to tech stocks](https://longbridge.com/en/news/296383193.md)
- [Allarity Therapeutics secures CLIA certification for in-house DRP testing lab](https://longbridge.com/en/news/291945556.md)
- [U.S. kindergarten vaccine coverage falls, CDC says](https://longbridge.com/en/news/296136711.md)
- [Allarity Therapeutics wins key US patent for stenoparib DRP companion diagnostic through 2042](https://longbridge.com/en/news/291279513.md)
- [Generic drug sector seeks policy fixes after Trump tariff threat](https://longbridge.com/en/news/293501714.md)